The 2026 Digestive Disease Week (DDW) is quickly approaching. From May 2 through May 5, in Chicago, Illinois, DDW is a major global gathering for gastrointestinal and hepatology professionals from around the world. With four days packed with informative sessions and ground-breaking research presentations, we’re taking the time to highlight sessions focusing on ulcerative colitis.

While there are many IBD sessions currently scheduled that focus on both ulcerative colitis and Crohn’s disease, and IBD in general, the following sessions focus on ulcerative colitis. All times and dates are accurate as of March 25, 2026. View the complete Digestive Disease Week 2026 schedule for the full look at currently scheduled sessions. 

Sessions on Ulcerative Colitis During DDW 2026

Saturday, May 2

  • Innate Immune Training with R-3750 Induces a Treg Reset Phenotype and Coordinated Mucosal Repair in Ulcerative Colitis: Multi-Omic Evidence from a First-in-Human Study
    • 8:15 AM – 8:30 AM
  • Icotrokinra, the First Targeted Oral Peptide that Selectively Blocks the Interleukin-23 Receptor, Reduces Systemic and Tissue Inflammatory Burden in Ulcerative Colitis: Results from the ANTHEM-UC Study
    • 8:30 AM – 8:45 AM
  • CAR T-Cell Therapy and Ulcerative Colitis Activity: Baseline Treatment Exposure and Post-Infection De-Escalation in a Multicenter Real-World Cohort
    • 8:30 AM – 8:45 AM
  • The Anti-TL1A Monoclonal Antibody Tulisokibart Inhibits Inflammatory and Fibrosis Pathways: Results from a Phase 2 Ulcerative Colitis Study
    • 8:45 AM – 9:00 AM
  • Integrative Multimodal Transcriptomic Analysis Reveals Stromal Drivers of Anti-TNF Failure in Ulcerative Colitis
    • 9:15 AM – 9:30 AM
  • Temporal Trends in Corticosteroids Use and Hospitalization in Ulcerative Colitis: Results from a Longitudinal Population-Based Cohort from 1970–2019
    • 10:15 AM – 10:30 AM
  • Temporal Trends in Major Abdominal Surgery for Ulcerative Colitis: A Longitudinal Population-Based Cohort from 1970-2019
    • 11:15 AM – 11:30 AM
  • ARGES-UC: AI-Based Continuous Scoring for Disease Severity in Ulcerative Colitis Enhances Detection of Treatment Effects and Reduces Sample Size Requirements in Clinical Trials for Measuring Endoscopic Treatment Differences
    • 2:00 PM – 2:15 PM
  • AI Inflammation and Architectural Model Differentiates Active and Remission Ulcerative Colitis States Across Histological Scoring Systems
    • 2:30 PM – 2:45 PM
  • The AI-Based Red Density Score Predicts Relapse in Ulcerative Colitis – The PROCEED-UC Trial
    • 3:00 PM – 3:15 PM
  • Machine Learning-Derived Blood Gene Signatures Enable Non-Invasive Stratification of Endoscopic Disease Severity in Ulcerative Colitis
    • 3:15 PM –3:30 PM
  • Updates in the Management of Ulcerative Colitis
    • 4:00 PM – 4:20 PM
  • Veillonella Parvula Exacerbates Intestinal Mucus Barrier Dysfunction in Ulcerative Colitis by Suppressing GPR41/β-Catenin Signaling
    • 5:00 PM – 5:15 PM

Sunday, May 3

  • Recent Advances in the Management of Acute Severe Ulcerative Colitis
    • 8:00 AM – 8:15 AM
  • Colonic Barrier Homeostasis in Ulcerative Colitis Before and After Night Shift Work
    • 8:45 AM – 9:00 AM
  • Efficacy of Icotrokinra, The First Targeted Oral Peptide that Selectively Blocks the Interleukin-23 Receptor in Ulcerative Colitis Patients With or Without Prior Intolerance or Inadequate Response to Advanced Therapies: Results from the ANTHEM-UC Study
    • 3:15 PM – 3:30 PM
  • JAK vs. TNF Inhibitors: Propensity Score-Adjusted Perioperative Safety After Surgery for Ulcerative Colitis – A NSQIP IBD Collaborative Cohort Study
    • 4:00 PM – 4:15 PM
  • Upadacitinib Vs. Corticosteroid for the Management of Ulcerative Colitis Flares: A Multicentre Prospective Study
    • 4:15 PM – 4:30 PM
  • Comparative Effectiveness of High-Dose Versus Standard-Dose Advanced Therapies in Ulcerative Colitis: A 14,962-Patient Real-World Cohort Study Using a Federated Electronic Health Record Network
    • 5:00 PM – 5:15 PM
  • Real World Outcomes of Upadacitinib Compared with Ustekinumab, Risankizumab, Mirikizumab, and Guselkumab as Second-Line Therapy in Ulcerative Colitis After Infliximab Exposure
    • 5:15 PM – 5:30 PM

Monday, May 4

  • Predicting Histological Activity in Ulcerative Colitis Using AI-Driven Endoscopic Disease Scoring
    • 8:36 AM – 8:48 AM
  • Impact of Obefazimod Treatment on Histologic and Combined Histologic-Endoscopic Outcomes in Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Abtect-1 and Abtect-2 Phase 3, Double-Blind, Placebo-Controlled Induction Trials
    • 10:00 AM – 10:15 AM
  • Safety and Efficacy of Ustenkinumab in Pediatric Ulcerative Colitis (UC): Results from the Phase 3 UNIFI JR Study
    • 10:15 AM – 10:30 AM
  • Racial and Gender Disparities in Rates of Colectomy in Ulcerative Colitis Patients: A Retrospective National Cohort Study
    • 10:24 AM – 10:36 AM
  • Efficacy of Etrasimod in Biologic/Janus Kinase Inhibitor-Naive Patients with Mildly to Moderately Active Ulcerative Colitis: Results from the GLADIATOR Trial
    • 11:00 AM – 11:15 AM 
  • Elective Colectomy Vs. Continuing Medical Therapy in Ulcerative Colitis: Evidence of a Survival Benefit from a Nationwide Study
    • 2:30 PM – 2:45 PM
  • Targeting the CGMP-PKG Stromal Axis: A Single-Cell Dissection of Colitis Associated Fibrosis and Colorectal Cancer in Ulcerative Colitis
    • 2:45 PM – 3:00 PM
  • A Meta-Analysis on the Impact of Prior Appendectomy on Colectomy Rates in Patients with Ulcerative Colitis
    • 2:45 PM – 3:00 PM
  • Transmural Ulcerative Colitis Single-Cell RNA Sequencing Atlas Reveals Fibroblast Heterogeneity and Intercellular Interactions
    • 3:17 PM – 3:30 PM
  • Phytosphingosine Derived From Faecalibacterium Prausnitzii-Derived Extracellular Vesicles Attenuates Ulcerative Colitis Via Targeting of LRP6
    • 4:45 PM – 5:00 PM
  • Mechanistic Insights into the Novel Protective Role of Paneth Cell Metaplasia in the Inflamed Colonic Epithelium of Ulcerative Colitis
    • 4:45 PM – 5:00 PM
  • Efficacy and Tolerability of Plant-Based Diet in Ulcerative Colitis in Remission: A Randomised Controlled Trial
    • 5:00 PM – 5:15 PM

Tuesday, May 5

  • Surreptitious Corticosteroid Use Identified by Formal Pharmacokinetic and HPA-AXIS Testing in a Phase 3 Ulcerative Colitis Clinical Trial
    • 9:15 AM – 9:30 AM
  • Sustained Symptomatic Relief and Disease Clearance Through 50 Weeks of Treatment with Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis in the Phase 2 ARTEMIS-UC Study
    • 10:15 AM – 10:30 AM
  • Preclinical Anti-Integrin AVB6 Autoantibodies in Ulcerative Colitis: Validation of Predictive Performance, Early Life Emergence and Environmental Modifiers Across Multiple Population-Based Cohorts
    • 2:15 PM – 2:30 PM

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.